Janney Montgomery Scott
SPRY icon

Janney Montgomery Scott’s ARS Pharmaceuticals SPRY Stock Holding History

Janney Montgomery Scott’s Portfolio SPRY Stock Details SPRY Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$16.5M Buy
2,064,498
+48,034
+2% +$413K 0.03% 511
2026
Q1 		$16.2M Buy
2,016,464
+728,632
+57% +$6.98M 0.04% 412
2025
Q4 		$15M Buy
1,287,832
+74,812
+6% +$728K 0.03% 458
2025
Q3 		$12.2M Buy
1,213,020
+621,595
+105% +$8.92M 0.03% 523
2025
Q2 		$10.3M Buy
591,425
+142,756
+32% +$2.06M 0.03% 552
2025
Q1 		$5.64M Buy
448,669
+421,511
+1,552% +$5.07M 0.02% 731
2024
Q4 		$287K Sell
27,158
-2,000
-7% -$28K ﹤0.01% 2338
2024
Q3 		$423K Buy
29,158
+4,672
+19% +$55.6K ﹤0.01% 2079
2024
Q2 		$208K Hold
24,486
– – ﹤0.01% 2431
2024
Q1 		$250K Buy
24,486
+881
+4% +$6.57K ﹤0.01% 2445
2023
Q4 		$129K Sell
23,605
-467
-2% -$2.05K ﹤0.01% 2529
2023
Q3 		$91K Sell
24,072
-15,897
-40% -$104K ﹤0.01% 2485
2023
Q2 		$268K Sell
39,969
-10,274
-20% -$68.6K ﹤0.01% 2298
2023
Q1 		$327K Sell
50,243
-3,471
-6% -$26.7K ﹤0.01% 1998
2022
Q4 		$458K Sell
53,714
-28,319
-35% -$184K ﹤0.01% 1835
2022
Q3 		$433K Sell
82,033
-6,425
-7% -$31.7K ﹤0.01% 1791
2022
Q2 		$379K Buy
88,458
+3,892
+5% +$13.6K ﹤0.01% 1766
2022
Q1 		$297K Sell
84,566
-165
-0.2% -$718 ﹤0.01% 1889
2021
Q4 		$564K Buy
84,731
+69,203
+446% +$562K ﹤0.01% 1642
2021
Q3 		$155K Sell
15,528
-580
-4% -$14.3K ﹤0.01% 2198
2021
Q2 		$498K Buy
16,108
+248
+2% +$7.95K ﹤0.01% 1638
2021
Q1 		$692K Buy
15,860
+4,903
+45% +$232K ﹤0.01% 1388
2020
Q4 		$508K Buy
+10,957
New +$366K ﹤0.01% 1561

Other funds holding SPRY

RCM
RA Capital Management Boston, Massachusetts $11.5B AUM 168.77% 1-Year Est. Return
RCMNY
Rubric Capital Management (New York) New York $10.9B AUM 70.31% 1-Year Est. Return
O
OrbiMed New York $5.4B AUM 163.13% 1-Year Est. Return
DM
Deerfield Management New York $9.59B AUM 113.36% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
TCM
Tyro Capital Management Miami, Florida $446M AUM 84.15% 1-Year Est. Return
Aberdeen Group
Aberdeen Group Edinburgh, United Kingdom $71.2B AUM 41.74% 1-Year Est. Return
SOCM
SR One Capital Management Wayne, Pennsylvania $1.04B AUM 262.99% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Capital World Investors
Capital World Investors Los Angeles, California $846B AUM 46.74% 1-Year Est. Return

Janney Montgomery Scott's SPRY Position: Q2 2026 in Review

Janney Montgomery Scott increased its ARS Pharmaceuticals (SPRY) stake by 2.4% in Q2 2026, buying an estimated $413K and bringing the position to 2,064,498 shares worth $16.5M. The position accounts for 0.03% of the portfolio, ranked #511.

Janney Montgomery Scott first reported a position in SPRY in Q4 2020 and has held it in 23 quarters since. 209 funds tracked by Wall St. Rank hold SPRY as of Q2 2026.

  • Janney Montgomery Scott held 2,064,498 shares of ARS Pharmaceuticals worth $16.5M as of Q2 2026.
  • Janney Montgomery Scott bought 48,034 ARS Pharmaceuticals shares in Q2 2026, an estimated $413K.
  • ARS Pharmaceuticals made up 0.03% of Janney Montgomery Scott's portfolio in Q2 2026, its #511 holding.
  • Janney Montgomery Scott first reported a position in ARS Pharmaceuticals in Q4 2020 and has held it in 23 quarters since.
  • 209 funds tracked by Wall St. Rank held ARS Pharmaceuticals as of Q2 2026.

Based on Janney Montgomery Scott's 13F filing for Q2 2026, filed 5 Aug 2026.